Asthma (Diagnosis)STARDUSTNCT07253883
A Study to Understand the Accuracy of a New Breathing Device Compared to Standard Testing for Asthma and COPD
An observational study of Asthma (Diagnosis) and COPD (Chronic Obstructive Pulmonary Disease), run by Liverpool Heart and Chest Hospital NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
The diagnosis of either asthma or chronic obstructive pulmonary disease (COPD) is currently based on a combination of symptoms, different lung tests and sometimes a 'trial by treatment'. Read more about this study
- Who is it for?
- Ages 18 to 110 years
- Conditions the study is for
- Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease)
- What is being tested?
- Partial pressure of CO2 during tidal breathing, FENO and Spirometry
- How many people
- 1,200 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 15 Sep 2026to 19 May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 110 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants with a suspicion of asthma and/or COPD
Who may be able to join
- Age ≥ 18 years
- Referred for respiratory diagnostic testing with a clinical suspicion of asthma or COPD
- Participant is willing and able to provide informed consent
Who cannot join
- Referred for respiratory diagnostic testing for a condition other than asthma or COPD, with no mention in the referral of a clinical suspicion of COPD or asthma
- Participants who, in the opinion of the chief investigator, or their delegate, are unlikely to comply with the requirements of the study
- Inability to give written informed consent
- Participants who are acutely unwell
- Patients unable to breathe through their mouths e.g. tracheostomy patients
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Thomas FitzMaurice, MBChB BSc PGCME MRCP(UK) PhD contact
United Kingdom1 site, 1 recruiting
- Recruiting
Liverpool Heart and Chest Hospital NHS Foundation Trust
Liverpool, Merseyside, L14 3PE
Freddy Frost, BMedSci BMBS MRCP MD, 0151 600 1616, freddy.frost@lhch.nhs.uk
About this study
Official title: A Diagnostic Accuracy Study: N-Tidal Assessment for Respiratory Diagnosis Compared to Using Standard Testing
The diagnosis of either asthma or chronic obstructive pulmonary disease (COPD) is currently based on a combination of symptoms, different lung tests and sometimes a 'trial by treatment'. Both COPD and Asthma tests currently include forced breathing using a test known as spirometry which can be difficult and uncomfortable for people to perform and needs expert interpretation. Asthma can require multiple tests in sequence which can make the process of diagnosis long and inconvenient for patients. In the UK, there have been challenges providing enough testing for COPD and asthma, in part because the tests are challenging to provide in the community to everyone who needs one.
The STARDUST study aims to test and develop new ways of diagnosing asthma and COPD that are quick, accurate and easy for patient and healthcare professionals to perform. People who have been referred for routine lung testing will breathe normally in and out into a handheld device called the N-Tidal Handset for 75 seconds. This device measures how the level of carbon dioxide (CO2) changes in the breath as people breath through it. The information gathered on the N-Tidal Handsets, called breath records or capnograms, will not be used to alter the diagnosis of any participants in the study.
Read more
After the capnograms have been collected, the research team will test 'algorithms' that have been developed using artificial intelligence, to see if they can accurately identify the correct diagnosis. Information collected in the study will also be used to make improvements in these algorithms.
If confirmed to be accurate, these algorithms could be used in clinical practice to help healthcare professionals make faster, more accessible and accurate diagnoses, especially in settings like GP clinics in the community where access to specialist tests may be limited.
Read the detailed description
COPD is one of the leading causes of disability and in the top five causes of death worldwide. Early diagnosis and treatment are essential to slow the decline of lung function and improve quality of life.
The current standard for diagnosing COPD is spirometry; an effort-dependent test that requires supervised use, by a specifically trained medical professional, in a clinic-based environment. It is estimated that up to 2/3 of cases are undiagnosed suggesting that there is a significant care gap in the ability to accurately diagnose COPD.
Asthma is a chronic respiratory disease, characterised by airway inflammation and hyper-responsiveness. In 2019 affected an estimated 262 million people. Early diagnosis and treatment are important to reduce symptoms, exacerbations and mortality and to improve overall quality of life. The confirmation of reversible airflow obstruction using pre- and post-bronchodilator (BD) spirometry is needed to confirm a diagnosis in those suspected as having asthma without evidence of inflammation in the airways or blood.
Spirometry can be challenging for patients to perform, is time consuming and can be challenging to deliver at the scale required by the population.
TidalSense have been developing respiratory diagnostic devices that could offer simpler, safe, fast, reliable and precise tests to diagnose both COPD and asthma.
It is anticipated that successfully meeting the primary objectives of this study will result in data on the diagnostic accuracy of the COPD diagnostic models and could lead to the development and improvement of all diagnostic algorithms used in the study. This may contribute to a range of future clinical benefits:
- Accurate diagnosis of asthma and/or COPD
- Accurate detection of severe COPD in patients who are likely or highly likely to have COPD
- Improved ease of testing for asthma and/or COPD for patients and healthcare professionals
- Clearer differentiation between asthma and COPD in patients with overlapping symptoms
These benefits could enable quicker testing, improve patient experience (relaxed breathing instead of forced breathing), and improve patient access to testing compared to current diagnostic pathways and reduce misdiagnosis.
- Being tested
- Partial pressure of CO2 during tidal breathing, FENO, Spirometry
- Keywords
- Asthma, COPD, End tidal CO2, Diagnostics, Machine learning
- Medical subject headings
- Asthma, Disease, Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Partial pressure of CO2 during tidal breathingDiagnostic test
Partial pressure of CO2 during tidal breathing for diagnosis of asthma or COPD
FENODiagnostic test
Also called Fractional exhaled nitric oxide
Fractional exhaled nitric oxide
SpirometryDiagnostic test
Spirometry with or without bronchodilation (if indicated)
| Study group | Role | What they receive |
|---|---|---|
| Asthma | Patients with suspected asthma Receives: Diagnostic Test: Partial pressure of CO2 during tidal breathing; Diagnostic Test: FENO; Diagnostic Test: Spirometry | |
| COPD | Patients with suspected COPD Receives: Diagnostic Test: Partial pressure of CO2 during tidal breathing; Diagnostic Test: FENO; Diagnostic Test: Spirometry |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diagnostic accuracy of the diagnostic algorithms of N-Tidal Diagnose 1
PPV, NPV, Sensitivity, Specificity compared to clinician diagnosis of COPD
Measured: At time of testing
Diagnostic accuracy of prototype diagnostic algorithms
Prototype asthma diagnostic algorithms (index test; PPV, NPV, Sensitivity, Specificity) trained using a combined capnogram dataset from this and previous studies, compared to clinician diagnosis of asthma
Measured: At time of testing
Secondary outcomes (2)
Diagnostic accuracy of the N-Tidal Diagnose 1 severity algorithm
Diagnostic accuracy (PPV, NPV, Sensitivity, Specificity) of the N-Tidal Diagnose 1 severity algorithm in those with a confirmed diagnosis of COPD. Diagnostic accuracy (PPV, NPV, Sensitivity, Specificity) of the diagnostic algorithms embedded in NTidal Diagnose 1 v1.0 in relevant subgroups. Diagnostic accuracy (PPV, NPV, Sensitivity, Specificity) of the pre-production asthma diagnostic algorithms trained using a combined capnogram dataset from this and previous studies in relevant prespecified subgroups. Exploratory analysis of novel machine learning diagnostic algorithms for COPD and asthma.
Measured: At time of diagnosis
Feasibility and acceptability outcomes
Visual Analogue Score (VAS) following N-Tidal, spirometry and FeNO (ease of use and comfort for participants, ease of use only for administering healthcare professionals) in a subset of participants. Percentage of participants with a clinical suspicion of COPD with adequate N-Tidal Handset breath record capture, sufficient to generate a diagnostic output using N-Tidal Diagnose 1 v1.0 diagnostic algorithms. Percentage of participants with a clinical suspicion of asthma with adequate N-Tidal Handset breath record capture, sufficient to generate a diagnostic output using prototype asthma diagnostic algorithms.
Measured: At time of diagnosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2025
- Study start15 Sep 2026
- Primary completion19 May 2027 (estimated)
- Study completion19 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Asthma (Diagnosis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- TidalSense
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07253883
- Sponsor's protocol ID
- 1694
- Acronym
- STARDUST
- Status last verified
- Oct 2026
- First submitted
- 19 Nov 2025
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data may be shared for future research under appropriate governance as per the terms of the collaboration agreement between TidalSense and the Liverpool Heart and Chest Hospital NHS Foundation Trust.
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Diagnostic Accuracy Study: N-Tidal Assessment for Respiratory Diagnosis Compared to Using Standard Testing
- ClinicalTrials.gov ID
- NCT07253883
- Acronym / sponsor ID
- STARDUST / 1694
- Keywords
- Asthma, COPD, End tidal CO2, Diagnostics, Machine learning
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- Liverpool Heart and Chest Hospital NHS Foundation TrustUniversity, hospital or other
- Collaborators
- TidalSense
- Study start
- 15 Sep 2026 (actual)
- Primary completion
- 19 May 2027 (estimated)
- Study completion
- 19 May 2027 (estimated)
- First posted
- 28 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The diagnosis of either asthma or chronic obstructive pulmonary disease (COPD) is currently based on a combination of symptoms, different lung tests and sometimes a 'trial by treatment'. Both COPD and Asthma tests currently include forced breathing using a test known as spirometry which can be difficult and uncomfortable for people to perform and needs expert interpretation. Asthma can require multiple tests in sequence which can make the process of diagnosis long and inconvenient for patients. In the UK, there have been challenges providing enough testing for COPD and asthma, in part because the tests are challenging to provide in the community to everyone who needs one.
The STARDUST study aims to test and develop new ways of diagnosing asthma and COPD that are quick, accurate and easy for patient and healthcare professionals to perform. People who have been referred for routine lung testing will breathe normally in and out into a handheld device called the N-Tidal Handset for 75 seconds. This device measures how the level of carbon dioxide (CO2) changes in the breath as people breath through it. The information gathered on the N-Tidal Handsets, called breath records or capnograms, will not be used to alter the diagnosis of any participants in the study.
After the capnograms have been collected, the research team will test 'algorithms' that have been developed using artificial intelligence, to see if they can accurately identify the correct diagnosis. Information collected in the study will also be used to make improvements in these algorithms.
If confirmed to be accurate, these algorithms could be used in clinical practice to help healthcare professionals make faster, more accessible and accurate diagnoses, especially in settings like GP clinics in the community where access to specialist tests may be limited.
Detailed description
COPD is one of the leading causes of disability and in the top five causes of death worldwide. Early diagnosis and treatment are essential to slow the decline of lung function and improve quality of life.
The current standard for diagnosing COPD is spirometry; an effort-dependent test that requires supervised use, by a specifically trained medical professional, in a clinic-based environment. It is estimated that up to 2/3 of cases are undiagnosed suggesting that there is a significant care gap in the ability to accurately diagnose COPD.
Asthma is a chronic respiratory disease, characterised by airway inflammation and hyper-responsiveness. In 2019 affected an estimated 262 million people. Early diagnosis and treatment are important to reduce symptoms, exacerbations and mortality and to improve overall quality of life. The confirmation of reversible airflow obstruction using pre- and post-bronchodilator (BD) spirometry is needed to confirm a diagnosis in those suspected as having asthma without evidence of inflammation in the airways or blood.
Spirometry can be challenging for patients to perform, is time consuming and can be challenging to deliver at the scale required by the population.
TidalSense have been developing respiratory diagnostic devices that could offer simpler, safe, fast, reliable and precise tests to diagnose both COPD and asthma.
It is anticipated that successfully meeting the primary objectives of this study will result in data on the diagnostic accuracy of the COPD diagnostic models and could lead to the development and improvement of all diagnostic algorithms used in the study. This may contribute to a range of future clinical benefits:
- Accurate diagnosis of asthma and/or COPD
- Accurate detection of severe COPD in patients who are likely or highly likely to have COPD
- Improved ease of testing for asthma and/or COPD for patients and healthcare professionals
- Clearer differentiation between asthma and COPD in patients with overlapping symptoms
These benefits could enable quicker testing, improve patient experience (relaxed breathing instead of forced breathing), and improve patient access to testing compared to current diagnostic pathways and reduce misdiagnosis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Asthma | – | Diagnostic Test: Partial pressure of CO2 during tidal breathing, Diagnostic Test: FENO, Diagnostic Test: SpirometryPatients with suspected asthma |
| COPD | – | Diagnostic Test: Partial pressure of CO2 during tidal breathing, Diagnostic Test: FENO, Diagnostic Test: SpirometryPatients with suspected COPD |
Who may qualify
- Ages
- 18 to 110 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants with a suspicion of asthma and/or COPD
Key inclusion criteria (3 listed)
- Age ≥ 18 years
- Referred for respiratory diagnostic testing with a clinical suspicion of asthma or COPD
- Participant is willing and able to provide informed consent
Key exclusion criteria (5 listed)
- Referred for respiratory diagnostic testing for a condition other than asthma or COPD, with no mention in the referral of a clinical suspicion of COPD or asthma
- Participants who, in the opinion of the chief investigator, or their delegate, are unlikely to comply with the requirements of the study
- Inability to give written informed consent
- Participants who are acutely unwell
- Patients unable to breathe through their mouths e.g. tracheostomy patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Partial pressure of CO2 during tidal breathingPartial pressure of CO2 during tidal breathing for diagnosis of asthma or COPD | Diagnostic test | Asthma, COPD |
| FENOAlso: Fractional exhaled nitric oxideFractional exhaled nitric oxide | Diagnostic test | Asthma, COPD |
| SpirometrySpirometry with or without bronchodilation (if indicated) | Diagnostic test | Asthma, COPD |
Primary outcome
Diagnostic accuracy of the diagnostic algorithms of N-Tidal Diagnose 1
Time frame: At time of testing
PPV, NPV, Sensitivity, Specificity compared to clinician diagnosis of COPD
Diagnostic accuracy of prototype diagnostic algorithms
Time frame: At time of testing
Prototype asthma diagnostic algorithms (index test; PPV, NPV, Sensitivity, Specificity) trained using a combined capnogram dataset from this and previous studies, compared to clinician diagnosis of asthma
2 secondary outcomes
Diagnostic accuracy of the N-Tidal Diagnose 1 severity algorithm
Time frame: At time of diagnosis
Feasibility and acceptability outcomes
Time frame: At time of diagnosis
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Individual participant dataSharing planned: Yes. Data may be shared for future research under appropriate governance as per the terms of the collaboration agreement between TidalSense and the Liverpool Heart and Chest Hospital NHS Foundation Trust.
Related trials for Asthma (Diagnosis)
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Thomas FitzMaurice, MBChB BSc PGCME MRCP(UK) PhD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Asthma (Diagnosis) and COPD (Chronic Obstructive Pulmonary Disease), run by Liverpool Heart and Chest Hospital NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hassan Burhan, MBChB FRCP (0151 254 3036, Hassan.Burhan@liverpoolft.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diagnostic accuracy of the diagnostic algorithms of N-Tidal Diagnose 1 (time frame: At time of testing). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.